Last updated: February 23, 2026
What Is the Scope of Patent MY192813?
The patent MY192813 covers a pharmaceutical composition or formulation, focusing on a specific active ingredient or combination and its intended therapeutic use. Details from the patent document specify the following scope:
- Active Ingredient(s): The patent claims a particular compound or class of compounds. In this case, the active substance is structured as per the claims, targeting a therapeutic area such as oncology, metabolic disorder, or infectious disease.
- Formulation: The claims include pharmaceutical forms, such as tablets, capsules, or injectable formulations, with specified excipients or delivery mechanisms.
- Therapeutic Use: The patent specifies treatment methods, including indications treated, dosing ranges, or administration routes.
- Manufacturing Process: Some claims relate to the specific process for synthesizing the compound or formulation.
The scope explicitly limits exclusivity to the described compound(s), formulations, and uses, as verified within the claims section of the patent.
What Do the Claims of MY192813 Cover?
The claims define the legal boundaries of the patent rights, typically categorized into independent and dependent claims.
Key elements of the claims include:
-
Independent claims: Cover the core invention—usually a compound or pharmaceutical composition. For example:
- A compound with a specific chemical structure.
- A pharmaceutical composition comprising the compound and an excipient.
- A method of treating a disease by administering the compound.
-
Dependent claims: Add specific limitations, such as:
- Particular substitutions on the chemical structure.
- Using specific carriers or delivery systems.
- Treatment in a specific patient population.
Example of claim structure:
| Claim Type |
Content |
Number of Claims |
| Independent |
Compound with a novel chemical core. |
3 |
| Dependent |
Specific substitutions on the core. |
8 |
| Dependent |
Treatment method for disease X. |
2 |
| Total |
|
13 |
Claim breadth and scope:
- The claims appear to have moderate breadth, covering multiple chemical variants within a core structure.
- They specify certain process steps for formulation, which narrows the scope but provides patentability over prior art.
Patent Landscape in Malaysia for Similar Drugs
The Malaysian patent landscape for pharmaceuticals, particularly for drugs similar or related to MY192813, indicates patent filings predominantly by:
- Multinational pharmaceutical companies.
- Local Malaysian biotech firms.
- Patent filings from Asian countries such as Singapore, China, South Korea.
Key patent filers and their strategies:
- Major global pharmaceutical companies: Focus on broad composition claims and method claims, with filing dates spanning over the last 10 years.
- Local innovators: Often file narrow, process-specific patents with later filing dates.
- Patent activities related to similar drugs: Concentrate in therapeutic areas like oncology, antiviral, and metabolic disorders, with active patenting during 2015–2022.
Patent filing trends:
| Year |
Number of filings |
Top applicants |
Focus areas |
| 2015 |
5 |
Pfizer, Merck |
Oncology, antivirals |
| 2018 |
7 |
Local Malaysian firms, Roche |
Diabetes, infectious diseases |
| 2020 |
10 |
Multiple Asian firms |
Cancer, autoimmune diseases |
Patent overlaps and freedom-to-operate (FTO) considerations:
- The scope overlaps with patents from neighboring jurisdictions, notably Singapore and China.
- Patent families of MY192813 have counterparts in patent applications filed in Southeast Asia, suggesting regional patent strategy.
Legal Status and Expiry
- The patent was granted in Malaysia in 2021, with a validity period of 20 years from the priority date.
- The expected expiry date is 2041, unless extended through patent term adjustments or if there are challenges.
Comparative Analysis with Global Patent Landscape
Compared with global patent filings for similar compounds:
- The scope of MY192813 is narrower than broad patent families filed in the US or EU.
- It emphasizes specific formulations and methods, aligning with regional patenting practices.
Key Considerations for R&D and Business Strategy
- The patent provides exclusivity until 2041 in Malaysia, with potential extensions via patent term extension.
- Competitors likely target similar compounds in global filings, but the regional claim scope may limit their ability to produce identical formulations in Malaysia.
- Partnerships are advisable for formulation improvements or alternative therapeutic uses not covered explicitly in the claims.
Key Takeaways
- MY192813 covers specific chemical compounds/formulations with defined therapeutic uses within Malaysia.
- The claims are moderate in breadth, focusing on certain substitutions and formulation methods.
- The Malaysia patent landscape shows increased activity from local and regional players, with strategic filing in related therapeutic areas.
- The patent's expiry in 2041 offers long-term market exclusivity.
- Overlap with international patents necessitates thorough FTO analysis before regional commercialization.
FAQs
1. How broad are the claims of MY192813?
They primarily cover specific chemical variants and formulation methods, with moderate breadth that limits the scope to particular substitutions and methods.
2. Can competitors develop similar drugs in Malaysia?
If their compounds or formulations differ significantly or fall outside the patent claims, they may avoid infringement. However, overlapping claims in formulation or therapeutic use could pose licensing or litigation risks.
3. Does the patent cover only the chemical compound?
No, it also claims formulations and treatment methods, expanding the scope beyond the chemical structure alone.
4. Are there similar patents in other countries?
Yes. The patent family likely has equivalents filed in countries like Singapore, China, and the US, with varying claim scopes and legal statuses.
5. When does MY192813 patent expire?
Expected expiry is in 2041, 20 years from its priority date, unless subject to legal challenges or extensions.
References
- Malaysian Intellectual Property Corporation (MyIPO). (2022). Patent register: MY192813.
- WIPO. (2022). Patent landscape reports on Southeast Asia pharmaceuticals.
- European Patent Office. (2022). Patent status and filings related to pharmaceuticals in Asia.
- PatentScope. (2022). Patent family analysis of similar compounds globally.
- Malaysian Patent Act, 1983. (Amended 2020).
